SANOFI-AVENTIS (EPA:SAN) ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
Directive transparence : information réglementée
24/02/2023 17:16
18/03/2023 15:00
16/03/2023 21:06
14/03/2023 19:27
02/03/2023 08:00
24/02/2023 17:16
23/02/2023 22:00
13/02/2023 08:30
03/02/2023 07:30
17/01/2023 20:44
17/01/2023 20:27